WHO says the outbreak is still uncontrolled—even as Washington puts serious money on the table. So what, exactly, can that money reach in time? If you're joining us mid-arc, here's the short version: Since June, DRC’s Bundibugyo Ebola outbreak has been uneven geographically, with Ituri at the center of the response and North Kivu a recurring concern. Earlier reports flagged persistent gaps in surveillance, treatment capacity, and response operations. ALIMA’s Ituri response includes four Ebola treatment centers with 239 beds, rapid diagnosis, community mobilization, and clinical research. This is Ebola Watch. Today, the outbreak’s geography is shifting, the funding picture just changed, and the treatment question is a lot less comforting than it ought to be. This one's from Xinhua News Agency:
Between Aug. 31 and Sept. 20, cases declined by about 26 percent in Ituri Province, the long-time epicenter of the outbreak, and by around 15 percent in Haut-Uele Province. North Kivu, however, recorded a 73-percent increase over the same period, she said.
So the outbreak’s center of gravity is moving. WHO says cases fell 26 percent in Ituri and 15 percent in Haut-Uele, while North Kivu jumped 73 percent in that same three-week window—toward communities that are already harder to reach. On the DRC Bundibugyo outbreak: WHO now says North Kivu is rising while Ituri and Haut-Uele decline. Belizaire says all seven affected provinces have distinct transmission patterns, so this isn't one trend playing out under different provincial names. And the count is 7,773 confirmed cases and 3,759 deaths as of Monday—confirmed, not suspected. Nearly 88 percent contact follow-up sounds substantial, but WHO says too many new infections still have no known epidemiological link. That’s where the response is leaking. Right. A 73 percent increase in North Kivu doesn’t mean every case there is untraced, but it makes those missing links more consequential. WHO’s conclusion is plain: the outbreak is still not under control. U.S. Department of State writes:
Today, on the margins of the High-Level Week of the 81st United Nations General Assembly in New York, the U.S. Department of State announced an additional $267 million in direct life-saving health and humanitarian assistance for the response to the Ebola outbreak in the Democratic Republic of the Congo (DRC).
The State Department just put $267 million more into this response—for treatment units, burial teams, protective gear, surveillance, and contact tracing. After those North Kivu numbers, that money is aimed at very concrete problems. And it brings total U.S. direct health and humanitarian assistance to $887 million. What matters is whether those teams and supplies reach provinces that are headed in opposite directions. Also, “up to an additional $500 million” at the G7 now comes with a receipt: $267 million of it. A meaningful chunk of that commitment is still on the table. The announcement came during UN General Assembly High-Level Week, even with President Tshisekedi absent from New York. The funding channel moved anyway. For outbreak control, though, coordination with Kinshasa and neighboring governments still determines how far it goes. From MSF Access:
There are currently no approved treatments for Ebola disease caused by BDBV, and three therapeutic candidates have been prioritised for clinical trials: the pan-ebolavirus antibody cocktail MBP134 and the antivirals remdesivir and obeldesivir. However, publicly available information provides limited insight into the access conditions that would apply if these products prove safe and effective.
We just heard about $267 million in new U.S. assistance. MSF’s reminder is brutal: for Bundibugyo Ebola, there are zero approved treatments to spend it on. There are three candidates headed for clinical trials: MBP134, remdesivir, and obeldesivir. But MSF says the public still has very limited information about the access terms if any of them proves safe and effective. And that can’t wait for an after-the-fact negotiation. If a trial works, clinicians in the DRC and Uganda need to know who can get the drug, how fast, and at what price—before the result lands. Exactly. A treatment pipeline is encouraging, but patients need access to it. MSF is pressing for those commitments while the evidence is still being built, when they can actually shape care on the ground. Here's Isabella Ward at WIRED:
While health officials were able to end the outbreak in Uganda through contact tracing, isolation, and clinical care, instability in the DRC means cases continue to climb. Millions of people have been displaced by ongoing violence, which has made contact tracing a “struggle,” according to Lurie.
The number that changes the map is displacement. WIRED says millions of people are moving amid violence, and contact tracing gets much harder when the people you need to find have been forced to move. And distrust directly disrupts the response. Attacks on Red Cross volunteers, damaged ambulances, delayed burial teams—each one breaks the chain that finds cases and prevents the next exposure. Put today’s facts together: 7,773 confirmed cases, a $267 million U.S. pledge, and zero approved treatments for Bundibugyo Ebola. CEPI redirected $100 million toward a vaccine, with efficacy trials expected this month—but any result still has to reach people navigating violence and displacement. Nicole Lurie’s warning in WIRED deserves attention, with one important limit: vaccine development may be necessary here, but it can’t replace safe access to communities, credible local partners, and a functioning follow-up system. This one's from Burundi Times:
The East African Community is seeking about $45 million to strengthen the region’s ability to detect and respond to Ebola and other high-consequence infectious diseases, as the bloc expands its network of mobile laboratories and trains health workers across its eight member states. The funding request reflects a broader push to build a regional surveillance and response system capable of detecting outbreaks quickly and managing them across national borders, a persistent challenge in a region where diseases can spread faster than national health systems can coordinate.
East Africa is asking for $45 million to make borders less porous to an outbreak—mobile labs, trained staff, faster alerts. With North Kivu surging, that’s basic outbreak control before a sick traveler becomes part of a cross-border chain. The EAC has 10 mobile laboratories across seven partner states now, including Beni, Busia, and Bwera, and wants 34 by the end of 2027. The key detail is the gap: 24 more labs are proposed, but there’s no deployment timetable for them. And the scale is hard to ignore. The U.S. just pledged $267 million; this eight-country regional system is seeking $45 million. A contact-tracing map doesn’t stop at a passport control booth, so regional surveillance can’t be a budget afterthought. They’re also training 120 frontline clinicians in Nairobi—on isolation, PPE, sample collection, and patient care. That’s practical capacity, but it needs to reach home facilities quickly, especially where displacement and insecurity make conventional tracing difficult. If your team needs this kind of briefing for your own industry, Lantern makes private daily podcast briefings on your competitors, market, or beat, delivered to your whole team’s private feed. Learn more at lantern podcasts dot com slash briefings, with a 14-day free trial.
We’re watching the EAC’s plan to expand its mobile laboratory network from 10 to 34 units by the end of 2027. Links to every story are in the show notes if you’d like to read more. That’s Ebola Watch for today. We’ll be back tomorrow. This is a Lantern Podcast.